Nurturing Hope Breaking the Barrier of BTK Inhibitor Resistance in CLL with NX-5948

Published / Modified Jun 16 2024
CSIMarket Team / CSIMarket.com


Nurix Therapeutics recently presented favorable outcomes from an ongoing clinical trial investigating the efficacy of NX-5948 in patients with relapsed refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024). This article provides an overview of the study, highlighting the response rate (ORR) of 69.2% observed in a patient population that exhibited resistance to Bruton's tyrosine kinase (BTK) inhibitors.

Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by the progressive accumulation of abnormal lymphocytes in the blood, bone marrow, and lymphoid organs. Despite advancements in treatment options, relapsed refractory CLL remains a significant challenge, necessitating novel therapeutic approaches. Nurix Therapeutics is examining the potential of NX-5948, an investigational drug, to address this unmet medical need.


The ongoing clinical trial evaluated the safety and efficacy of NX-5948 in heavily pretreated patients with relapsed refractory CLL, including individuals with BTK inhibitor resistance mutations. Patients received NX-5948 either as a monotherapy or in combination with other CLL therapies. The treatment was administered orally at specified dose levels, and the response rate was assessed as a primary endpoint.


Results presented at the EHA2024 showcased promising outcomes for NX-5948 in this challenging patient population. Among the heavily pretreated patients, an response rate of 69.2% was observed. This significant response was seen in patients who had previously demonstrated resistance to Bruton's tyrosine kinase (BTK) inhibitors, underscoring the potential of NX-5948 as a therapeutic option for those with limited treatment alternatives.


The response rate of 69.2% observed with NX-5948 represents a notable achievement in patients with relapsed refractory CLL. The inclusion of individuals harboring BTK inhibitor resistance mutations further emphasizes the potential of this investigational drug. The precise mechanism of action underlying NX-5948's effectiveness in this specific patient population is yet to be fully elucidated but warrants further investigation.


The preliminary findings from the ongoing clinical trial demonstrate the promising potential of NX-5948 for patients with relapsed refractory CLL, including those with BTK inhibitor resistance mutations. The 69.2% response rate observed in this heavily pretreated population highlights the need for continued research and development of this novel therapeutic approach. Further studies are required to elucidate the mechanism of action and evaluate the long-term efficacy and safety profile of NX-5948, ultimately leading to its potential approval as a targeted therapy for CLL.

Sources for this article: Nurix Therapeutics Inc Press release, News Wire, Globe Newswire, Business wire, Pr newswire.... and CSIMarket.com Customer Analytics Research for Nurix Therapeutics Inc


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com